Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) saw an uptick in trading volume on Wednesday. Approximately 804,812 shares changed hands during mid-day trading, an increase of 164% from the average daily volume of 304,809 shares. The stock last traded at $18.80 and had previously closed at $18.15.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.
Get Our Latest Analysis on Daiichi Sankyo
Daiichi Sankyo Stock Down 6.5%
The company has a current ratio of 2.92, a quick ratio of 1.96 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $33.27 billion, a P/E ratio of 18.22, a P/E/G ratio of 2.15 and a beta of -0.10. The company has a 50 day simple moving average of $17.81 and a two-hundred day simple moving average of $17.60.
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.08. Daiichi Sankyo had a net margin of 12.13% and a return on equity of 16.31%. The firm had revenue of $3.77 billion for the quarter, compared to analysts’ expectations of $3.58 billion. On average, equities analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 EPS for the current fiscal year.
Daiichi Sankyo Company Profile
Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.
Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.
Further Reading
- Five stocks we like better than Daiichi Sankyo
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
